• Alias: BSI-201
    • A small-molecule iodobenzamide that appears to be cytotoxic in cells with DNA alterations or DNA damage, like that found in tumor cells with mutations in the ATM gene.
    • ATM encodes a serine/threonine protein kinase, and the mutations of the gene are associated with ataxia telangiectasia.
    • Once thought to inhibit PARP
    • Currently in phase 3 clinical trials for patients who benefited from initial treatment and phase 2 studies in ovarian cancer, uterine cancer, NSCLC, and glioblastoma
    • Recommended phase 2 dose: 4 to 8 mg/kg on days 1, 4, 8, and f the 21-day cycle
    Other topics in Targeted and Immunotherapy Agents